Barclays
PROF icon

Barclays’s Profound Medical PROF Stock Holding History

Barclays’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.59K Buy
+274
New +$1.86K ﹤0.01% 4964

Other funds holding PROF

Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
GA
Gagnon Advisors New York $182M AUM 52.04% 1-Year Est. Return
Letko, Brosseau & Associates
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.9B AUM 29.83% 1-Year Est. Return
Ring Mountain Capital
Ring Mountain Capital Tiburon, California $245M AUM 48.62% 1-Year Est. Return
Thompson Davis & Co
Thompson Davis & Co Richmond, Virginia $149M AUM 10.53% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Perkins Capital Management
Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return
Crescent Grove Advisors
Crescent Grove Advisors Lake Forest, Illinois $1.18B AUM 13.12% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return

Barclays's PROF Position: Q3 2026 in Review

Barclays opened a new position in Profound Medical (PROF) in Q3 2026: 274 shares worth $1.59K. The stake represents ﹤0.01% of the portfolio and ranks #4964 among its holdings.

19 funds tracked by Wall St. Rank hold PROF as of Q3 2026.

  • Barclays held 274 shares of Profound Medical worth $1.59K as of Q3 2026.
  • Profound Medical was a new Barclays position in Q3 2026.
  • Profound Medical made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4964 holding.
  • 19 funds tracked by Wall St. Rank held Profound Medical as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.